Veracyte’s Prosigna breast cancer test gains Medicare coverage
Veracyte announced that its Prosigna Breast Risk of Recurrence test received Medicare coverage through Palmetto GBA’s MolDX program. The coverage, effective August 19, 2026, applies to postmenopausal women with early‑stage ER‑positive breast cancer meeting Medicare criteria. The company said the decision follows the OPTIMA trial, which showed the test could spare more than two‑thirds of clinically high‑risk patients from chemotherapy. CEO Marc Stapley highlighted the milestone as a step toward broader adoption and patient access.
Why it matters
The coverage creates a reimbursement pathway for eligible patients, likely expanding test utilization and supporting Veracyte’s revenue growth. The company also offers financial assistance programs for uninsured or underinsured patients, which may further increase adoption.
Key facts
- 1Medicare coverage for Prosigna was secured through Palmetto GBA’s MolDX program. stocktitan.net
- 2Coverage is effective as of August 19, 2026. stocktitan.net
- 3The reimbursement applies to postmenopausal women with early‑stage estrogen receptor positive breast cancer, stage I or II with 0‑3 positive lymph nodes. stocktitan.net
- 4The OPTIMA phase III trial showed that more than two‑thirds of clinically high‑risk patients could avoid chemotherapy with Prosigna‑guided treatment. stocktitan.net
- 5Veracyte launched Prosigna in the U.S. in June 2026. investing.com
- 6CEO Marc Stapley said the Medicare decision is a significant step to ensure patient access. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.